while miRNA profiles were prepared using preoperative biopsies. A preselected panel of 96 miRNAs, known to be of importance in malignancies, was used to test for significant differences between responsive (chemosensitive) and non-responsive (chemoresistant) cases. All data were normalized with GenEx Software Version 6.1 (MultiDAnalyses, Germany) and further analyzed using SPSS Version 22 (IBM, Germany) applying MannWhitney-U test for unpaired samples. A P-value < .05 was considered to be statistically significant. Results: After histologic examination, the cohort consisted of 12 non-responders and 21 responders with the following four miRNAs differentially expressed between both groups: hsa-let-7f-5p, hsa-miR-221-3p, hsa-miR-31-5p and hsa-miR-191-5p. The former three showed up-regulation in chemoresistant cases (P-values .025, .04, and .033) while the latter showed up-regulation in chemosensitive cases (P-value .014).
while miRNA profiles were prepared using preoperative biopsies. A preselected panel of 96 miRNAs, known to be of importance in malignancies, was used to test for significant differences between responsive (chemosensitive) and non-responsive (chemoresistant) cases. All data were normalized with GenEx Software Version 6.1 (MultiDAnalyses, Germany) and further analyzed using SPSS Version 22 (IBM, Germany) applying MannWhitney-U test for unpaired samples. A P-value < .05 was considered to be statistically significant. Results: After histologic examination, the cohort consisted of 12 non-responders and 21 responders with the following four miRNAs differentially expressed between both groups: hsa-let-7f-5p, hsa-miR-221-3p, hsa-miR-31-5p and hsa-miR-191-5p. The former three showed up-regulation in chemoresistant cases (P-values .025, .04, and .033) while the latter showed up-regulation in chemosensitive cases (P-value .014).
Conclusion:
In conclusion, we identified a panel of three miRNAs predicting chemoresistance as well as a single miRNA contributing to chemosensitivity. These miRNAs might function as prognostic biomarkers and enable clinicians to better predict the effect of or more reliably select patients benefitting from (neoadjuvant) chemotherapy.
Daratumumab Interference With Serum Protein Electrophoresis
Li Liu, Sarah Wheeler, PhD, Michael Shurin, MD, PhD; University of Pittsburgh Medical Center, Pittsburgh, PA Daratumumab is a fully human anti-CD38 IgG1-κ monoclonal antibody (mAb) approved by the US Food and Drug Administration in 2016 for the treatment of relapsed or refractory plasma cell myeloma. Since its adoption, concerns have been raised about the possibility of interference with the results of serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) assays, especially for IgG/κ myeloma cases. Although daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) is being evaluated, it has not been implemented in most clinical laboratories. SPE and IFE data in patients treated with daratumumab are rarely reported. We evaluated SPE and IFE results on patients being treated by daratumumab and present a representative case. Results: We found that daratumumab can be readily detected by both SPE and IFE in patients treated with a standard therapeutic dose using SPIFE 3000 (Helena Lab, Beaumont, TX). It migrates late in the γ zone and the trough level of weekly daratumumab corresponds to an IgG/κ M-protein band between 0.1 and 0.2 g/dL. In an example case, an 86-year-old woman with recurrent multiple plasmacytoma had no history of monoclonal proteins in her SPE and IFE in the past. In August 2016, she started weekly daratumumab therapy. On her next SPE and IFE, a monoclonal IgG/κ band appeared as an M-spike of 0.23 g/dL. With these results, her clinical diagnosis was changed to IgG/κ multiple myeloma. Conclusion: In conclusion, daratumumab can interfere with SPE and IFE interpretation in IgG/κ myeloma, as well as in any other monoclonal gammopathies. Before a better solution can be implemented, the laboratory should become familiar with the properties of daratumumab on SPE and IFE, and investigate the clinical history for therapeutic mAb use in suspicious cases to avoid misdiagnosis.
Aberrant Expression of Desmin in Primary Lung Cancer Is Observed Exclusively in Carcinomas With Neuroendocrine Differentiation

Sun A Kim, MD, Markku Miettinen, MD; National Institutes of Health, New York, NY
Objectives: Desmin is known to be expressed in mesenchymal tumor component of pulmonary and pleuropulmonary blastoma, sarcomatoid carcinoma, and salivary gland-type tumors arising in lung. However, desmin expression has not been reported in other types of primary lung cancers without mesenchymal tumor component. We identified cytoplasmic expression of desmin in a subset of primary lung cancers, and investigated pathologic and immunohistochemical characteristics of these cancers. Methods: Tissue microarrays were constructed with representative sections of lung tumors. Two pathologists reviewed the hematoxylin and eosin stains, and immunohistochemical stains p63, CK5/6, synaptophysin, chromogranin, CD56, desmin, MSA, MyoD1, to identify primary lung cancers and carcinoids that were subsequently classified based on World Health Organization classification. Two different anti-desmin antibodies (clone D33 and DE-R-11) were used with two different automated immunohistochemical staining platforms to confirm the consistency of desmin expression. Results: In total, 697 primary lung cancers and five carcinoid tumors were included in this study. There were eight desmin-positive carcinomas, consisting of one adenocarcinoma (1/308, 0.3%), three large cell neuroendocrine carcinomas (3/45, 6.7%), three combined large cell neuroendocrine carcinoma-adenocarcinomas (3/14, 21.4%), and one sarcomatoid carcinoma (1/4, 25.0%). One desmin-positive adenocarcinoma was moderately differentiated and showed focal neuroendocrine differentiation. Desmin-positive cells in sarcomatoid carcinoma were also positive for MSA, MyoD1 and Myf-4, consistent with skeletal muscle differentiation, which was not detected in
